Ascendis Pharma A ASND Cash Flow Statement (2014-2026)

NASDAQ ASND
$228.07 -1.98 (-0.86%)
At close: Sep 29, 2026 · 4:00 PM EDT
Reported Financials

Ascendis Pharma A Quarterly Cash Flow Statement

Periods 50 quarters
Latest Jun 2026

Ascendis Pharma A reported cash from operations of $327.42M and free cash flow of $327.42M for the quarter ended Jun 2026. This cash flow statement covers 50 quarters of results from Mar 2014 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-94.75M-121.33M-140.85M-86.77M-170.35M-211.62M-119.05M-132.23M-176.59M-93.48M-142.35M-117.79M-108.94M-41.11M-99.54M-43.98M-71.30M-39.07M736.80M240.57M
Depreciation and Depletion
4.33M4.76M4.83M4.57M4.44M4.62M4.76M4.94M5.04M5.19M4.74M4.60M4.68M4.65M4.78M4.88M4.28M5.47M4.94M5.31M
Share-based Compensation
15.67M16.18M22.41M17.93M13.65M14.15M14.69M21.65M18.71M17.12M18.77M28.05M28.51M28.02M26.88M33.98M35.82M34.87M35.54M34.42M
Deferred Taxes
Asset Writedowns and Impairment
7.90M-2.59M
Change in Working Capital
Change in Receivables
-6.20M3.02M-2.70M-3.51M-0.38M-5.57M-10.31M-1.21M-14.73M-9.17M-12.26M-12.34M31.78M-133.36M103.12M-54.32M-29.12M106.45M-42.59M-28.68M
Change in Inventory
-65.18M-23.03M-19.11M-9.48M-2.68M-27.24M-21.66M-18.59M-23.09M-21.30M-25.80M-19.94M-15.63M-32.25M2.67M-11.67M1.58M0.58M-15.00M4.38M
Change in Account Payables
51.18M-17.29M-4.87M13.12M14.69M23.89M15.28M-5.36M4.67M-10.82M-20.67M9.10M-8.19M48.08M-42.88M17.22M-8.80M-10.71M-24.65M34.53M
Other Working Capital Changes
1.36M1.36M2.47M1.44M3.77M2.13M1.79M10.31M-21.71M-1.03M0.12M0.32M-0.69M-4.26M0.68M2.77M6.12M2.03M-5.84M
Cash from Operations
-115.00M-141.06M-146.79M-132.73M-99.65M-144.55M-157.83M-166.74M-135.77M-45.70M-110.35M-66.02M-61.64M-93.16M-15.06M-8.31M2.52M-123.70M-9.04M327.42M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles
0.13M0.13M0.12M0.12M0.11M0.11M0.12M0.12M0.12M0.16M0.13M0.12M0.13M0.13M0.13M0.13M0.14M0.15M
Depreciation & Amortization (CF)Depreciation & Amortization
4.33M4.76M4.83M4.57M4.44M4.62M4.76M4.94M5.04M5.19M4.74M4.60M4.68M4.65M4.78M4.88M4.28M5.47M4.94M5.31M
Investing Activities
Capital Expenditures
-13.33M21.63M-4.29M-3.98M-3.19M20.65M-1.16M-0.48M-1.06M2.70M-0.22M-0.37M-0.51M1.08M
Sales of Property, Plant and Equipment
0.01M-0.01M0.02M0.03M0.01M-0.10M1.12M
Change in Intangibles
-14.78M-0.22M-0.37M-0.55M-0.41M-0.74M-4.91M-0.06M-3.95M-9.03M-3.76M
Cash from Investing Activities
24.09M-128.04M43.26M10.55M14.22M-0.81M226.10M51.13M24.19M7.16M7.77M0.65M-0.55M-0.39M-0.74M-4.91M-0.06M-3.95M-7.91M-3.32M
Financing Activities
Other financing activities
Debt Issuance and Repayment
Long-Term Debt Issuances
566.17M-1.25M152.17M-3.79M
Long-Term Debt Repayments
-2.76M-2.74M-2.85M-2.94M-3.03M-3.04M-3.09M-3.15M-3.23M-6.21M-7.68M-7.96M-10.04M-9.46M
Change in Capital Stock
Net Equity Issued and Repurchased
5.22M2.66M0.43M0.32M1.35M3.19M2.00M0.23M6.74M2.17M23.04M0.39M6.49M3.24M14.55M14.11M53.10M17.87M37.02M21.46M
Misc.
Cash from Financing Activities
437.05M-23.60M446.39M-2.38M-0.08M1.38M-0.75M-2.51M156.06M-6.51M20.01M-2.64M469.90M0.09M-18.96M7.90M45.42M31.90M-43.12M-53.61M
Exchange Rate Effect
1.20M10.51M4.36M-0.81M-2.23M2.26M-6.85M-1.11M0.62M-1.61M4.43M0.02M0.17M0.89M-9.03M-1.58M-1.84M-0.57M9.47M5.65M
Change in Cash
346.13M342.86M-124.57M-85.51M67.51M-118.13M44.48M
Free Cash Flow
-101.68M-162.69M-142.50M-128.76M-96.46M-165.21M-156.66M-166.26M-134.71M-48.39M-110.14M-65.65M-61.13M-94.23M-15.06M-8.31M2.52M-123.70M-9.04M327.42M
Net Cash Flow
346.13M-292.70M342.86M-124.57M-85.51M-143.99M67.51M-118.13M44.48M-45.05M-82.57M-68.01M407.70M-93.46M-34.75M-5.32M47.88M-95.75M-60.07M270.49M

Ascendis Pharma A Cash Flow Statement API

Pull Ascendis Pharma A's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=ASND&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY